This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
GSK to Invest $30B in U.S. R&D and Manufacturing Over 5 Years
by Zacks Equity Research
GSK commits $30B to U.S. R&D and manufacturing, with advanced AI-driven biopharma facilities set to expand jobs and innovation.
LLY's $5B Virginia Plant Plan: Will U.S. Manufacturing Shift Pay Off?
by Kinjel Shah
Eli Lilly will invest $5B in a new Virginia plant to make cancer drugs, creating 650 jobs amid Trump's tariff push.
NVO Stock Rises on Upbeat Phase III Data for Cagrilintide in Obesity
by Zacks Equity Research
Novo Nordisk stock rises as its next-generation subcutaneous obesity treatment candidate, cagrilintide, delivers meaningful weight loss in a phase III obesity study.
Why the Market Dipped But Eli Lilly (LLY) Gained Today
by Zacks Equity Research
Eli Lilly (LLY) concluded the recent trading session at $763.57, signifying a +2.06% move from its prior day's close.
AMGN vs. VKTX: Which Biotech Stock Is the Better Obesity Play?
by Sundeep Ganoria
Amgen's MariTide and Viking's VK2735 show promise in obesity, but pipeline strength and performance set the two biotech players apart.
Is ABBV Stock a Buy, Hold, or Sell After Its Almost 23% Rise YTD?
by Kinjel Shah
AbbVie surges 22.5% YTD as new drugs Skyrizi and Rinvoq drive growth, offsetting Humira losses and fueling long-term momentum.
Will Rybelsus' Updated EU Label Propel Fresh Growth Potential for NVO?
by Ahan Chakraborty
Novo Nordisk gains EU approval for adding the cardiovascular indication to Rybelsus' label, strengthening its edge in the competitive diabetes market.
Lilly Moves Past 50-Day SMA: Should You Consider Buying the Stock Now?
by Kinjel Shah
Eli Lilly shares move past the 50-day SMA as weight-loss drug data, rising sales and pipeline momentum fuel optimism.
Is Trending Stock Eli Lilly and Company (LLY) a Buy Now?
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
AbbVie Settles Rinvoq Patent Dispute: What It Means for the Stock
by Sundeep Ganoria
ABBV secures Rinvoq's market lead until 2037, boosting shares as strong sales and new indications fuel long-term growth prospects.
Where Does VKTX Stock Stand After the Obesity Pill Setback?
by Sundeep Ganoria
Viking Therapeutics faces pressure after mixed oral obesity pill trial results, raising safety concerns but still meeting key study goals.
Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Novartis, Pfizer and Bayer
by Zacks Equity Research
Big Pharma faces tariff risks, patent cliffs, and regulatory pressure, but innovation and strong pipelines keep Eli Lilly, J&J, Novartis, Pfizer, and Bayer in focus.
5 Large Drug Stocks to Watch Despite Industry & Macro Headwinds
by Kinjel Shah
In the Large-Cap Pharmaceuticals industry, Lilly, J&J, Novartis, Pfizer and Bayer are worth retaining amid macro pressure and rising innovation.
Is NVO's Major Restructuring Plan an Indication to Sell the Stock?
by Ahan Chakraborty
Novo Nordisk's sweeping restructuring plan cuts 9,000 jobs, targets DKK 8 billion in savings, and shifts focus to obesity and diabetes R&D.
Eli Lilly (LLY) Just Reclaimed the 50-Day Moving Average
by Zacks Equity Research
Good things could be on the horizon when a stock surpasses the 50-Day simple moving average. How should investors react?
LLY's Phase III Study on Jaypirca in Front-Line Leukemia Meets Goal
by Zacks Equity Research
Lilly's Jaypirca shows a strong survival benefit over chemoimmunotherapy in treatment-naive CLL/SLL, boosting its potential in front-line use.
Will LLY's Oncology Portfolio Provide Key Diversification Benefits?
by Ahan Chakraborty
Eli Lilly's oncology portfolio, led by Verzenio and Jaypirca, is adding diversification to its cardiometabolic-driven growth story.
Will Merck's Cost Cuts and New Drug Approvals Ease Headwinds?
by Kanishka Das
MRK expects strong Keytruda sales, new drug launches and $3B in planned cost savings to offset pressure from declining Gardasil sales and other headwinds.
Eli Lilly (LLY) Laps the Stock Market: Here's Why
by Zacks Equity Research
Eli Lilly (LLY) concluded the recent trading session at $738.17, signifying a +1.51% move from its prior day's close.
Here's How Much You'd Have If You Invested $1000 in Eli Lilly a Decade Ago
by Zacks Equity Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
NKTR Shares Surge 38.2% in a Week: Here's What You Should Know
by Zacks Equity Research
Nektar shares surge 38.2% on investor optimism on rezpeg's potential in atopic dermatitis after upbeat mid-stage study results.
Investing in Oncology: 3 Cancer Stocks With Promising Pipelines
by Kinjel Shah
Relay Therapeutics, Pyxis Oncology and Allogene Therapeutics drive cancer innovation with pivotal trials and promising drug candidates.
Pfizer's 6.9% Yield & Bullish Signal: A Prime Buying Opportunity?
by Tirthankar Chakraborty
Pfizer's strong Q2 results, high dividend yield, and bullish chart fuel optimism despite patent losses and rising competition.
Zacks Investment Ideas feature highlights: Church & Dwight, Eli Lilly and Viatris
by Zacks Equity Research
CEOs at Church & Dwight, Eli Lilly, and Viatris are buying shares after stock pullbacks, signaling insider confidence.
Insider Watch: 3 CEOs Buying the Dip
by Derek Lewis
Large-cap stocks CHD, LLY, and VTRS have seen their respective CEOs make purchases over the last month. What do they see?